Directors Dealings
Director dealings are proprietary transactions by executives, which are reportable under Art. 19 MAR. The publication of these transactions is an important contribution to the prevention of insider dealing and market manipulation. In addition, knowledge of such transactions is of great importance to the market, as these transactions provide indications of management's assessment of the company's future business prospects. The information presented here relates to companies that are under the supervision of BaFin.
APONTIS PHARMA AG: A reportable insider transaction was published on 14th May 2024. The reporting obligation was triggered by a person related to Closely associated.
Transaction reporting date: 14th May 2024,
The Insider Transaction was made by be executive GmbH 
. The transaction toke place on 13th May 2024. The order was executed at the trading place Tradegate. . The aggregated volume was 8.880,00 EUR, based on an average price of 8,88 EUR. The nature of the Investment was Buy.
APONTIS PHARMA AG: A reportable insider transaction was published on 14th May 2024. The reporting obligation was triggered by a person related to Management Board.
Transaction reporting date: 14th May 2024,
The Insider Transaction was made by Milz, Thomas . The transaction toke place on 13th May 2024. The order was executed at the trading place Tradegate. . The aggregated volume was 8.960,00 EUR, based on an average price of 8,96 EUR. The nature of the Investment was Buy.
APONTIS PHARMA AG: A reportable insider transaction was published on 13th May 2024. The reporting obligation was triggered by a person related to Other executive.
Transaction reporting date: 13th May 2024,
The Insider Transaction was made by Zimmermann, Thomas . The transaction toke place on 8th May 2024. The order was executed at the trading place Börse Düsseldorf. . The aggregated volume was 3.396,00 EUR, based on an average price of 8,49 EUR. The nature of the Investment was Buy.
APONTIS PHARMA AG: A reportable insider transaction was published on 13th May 2024. The reporting obligation was triggered by a person related to Other executive.
Transaction reporting date: 13th May 2024,
The Insider Transaction was made by Zimmermann, Thomas . The transaction toke place on 8th May 2024. The order was executed at the trading place XETRA. . The aggregated volume was 1.688,00 EUR, based on an average price of 8,44 EUR. The nature of the Investment was Buy.
APONTIS PHARMA AG: A reportable insider transaction was published on 13th May 2024. The reporting obligation was triggered by a person related to Other executive.
Transaction reporting date: 13th May 2024,
The Insider Transaction was made by Zimmermann, Thomas . The transaction toke place on 8th May 2024. The order was executed at the trading place Börse Stuttgart. . The aggregated volume was 1.692,00 EUR, based on an average price of 8,46 EUR. The nature of the Investment was Buy.
APONTIS PHARMA AG: A reportable insider transaction was published on 13th May 2024. The reporting obligation was triggered by a person related to Other executive.
Transaction reporting date: 13th May 2024,
The Insider Transaction was made by Zimmermann, Thomas . The transaction toke place on 8th May 2024. The order was executed at the trading place Baader Bank. . The aggregated volume was 1.688,00 EUR, based on an average price of 8,44 EUR. The nature of the Investment was Buy.
APONTIS PHARMA AG: A reportable insider transaction was published on 13th May 2024. The reporting obligation was triggered by a person related to Other executive.
Transaction reporting date: 13th May 2024,
The Insider Transaction was made by Zimmermann, Thomas . The transaction toke place on 8th May 2024. The order was executed at the trading place Tradegate. . The aggregated volume was 10.128,00 EUR, based on an average price of 8,44 EUR. The nature of the Investment was Buy.
APONTIS PHARMA AG: A reportable insider transaction was published on 5th May 2023. The reporting obligation was triggered by a person related to Closely associated.
Transaction reporting date: 5th May 2023,
The Insider Transaction was made by Reineke, Silke . The transaction toke place on 4th May 2023. The order was executed at the trading place Tradegate. . The aggregated volume was 36.625,00 EUR, based on an average price of 7,33 EUR. The nature of the Investment was Buy.
APONTIS PHARMA AG: A reportable insider transaction was published on 5th May 2023. The reporting obligation was triggered by a person related to Management Board.
Transaction reporting date: 5th May 2023,
The Insider Transaction was made by Milz, Thomas . The transaction toke place on 4th May 2023. The order was executed at the trading place Xetra. . The aggregated volume was 14.360,00 EUR, based on an average price of 7,18 EUR. The nature of the Investment was Buy.
| Type | Total | Last | Made by | Go to |
|---|---|---|---|---|
| Equity Story | 88 | 7th November 2024 | EQS Group AG | EQS |
| Corporate Research | 2 | 16th August 2024 | EQS Group AG | Corporate Research |
| Short Seller (DE) | 0 | - | - | SSR (DE) |
| Short Seller (UK) | 0 | - | - | SSR (UK) |
Disclaimer:
The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster.
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.
If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.